Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial

Honglei Luo, Wei Jiang, Li Ma, Peng Chen, Min Fang, Lingyu Ding, Yuhui Hua, Dexi Du, Zhao Jing, Ruifei Xie, Yaqi Song, Jiayang Wang, Rongjing Zhou, Zhifeng Tian, Shixiu Wu, Honglei Luo, Wei Jiang, Li Ma, Peng Chen, Min Fang, Lingyu Ding, Yuhui Hua, Dexi Du, Zhao Jing, Ruifei Xie, Yaqi Song, Jiayang Wang, Rongjing Zhou, Zhifeng Tian, Shixiu Wu

Abstract

Importance: Palliative radiotherapy (RT) is generally recommended for older patients with esophageal squamous cell carcinoma (ESCC) with poor prognosis. A new combination treatment is therefore needed.

Objective: To assess the efficacy and toxicity of RT plus icotinib vs RT alone in older patients with ESCC.

Design, setting, and participants: This randomized, multicenter, open-label, phase II clinical trial was conducted in China, with enrollment between January 1, 2015, and October 31, 2016. Patients aged 70 years or older with clinical stage T2 to T4, N0/1, M0/1a unresectable (because of comorbidities, T4 disease, unresectable lymph node, or refused surgery) ESCC were randomized 1:1 to receive RT plus icotinib or RT alone. Radiation was prescribed at 60 Gy in 30 fractions in both groups, and icotinib was administered at a dosage of 125 mg 3 times a day in the RT plus icotinib group. The last follow-up was completed on June 30, 2019, and data were analyzed from July 1 to September 30, 2019.

Interventions: Patients were randomized to either RT plus icotinib or RT alone.

Main outcomes and measures: The primary end point was overall survival (OS). Treatment-related toxic effects were evaluated. Immunohistochemistry was performed to analyze epidermal growth factor receptor (EGFR) expression if available.

Results: A total of 127 patients (median age, 76 years [range, 70-91 years]; 76 men [59.8%]) were enrolled and were eligible for survival analysis. Median OS was 24.0 (95% CI, 22.2-25.8) months in the RT plus icotinib group vs 16.3 (95% CI, 13.8-18.8) months in the RT group (hazard ratio, 0.53; 95% CI, 0.33-0.87; P = .008). No difference was observed in grades 3 or 4 adverse events. Patients with EGFR overexpression had a significantly better median overall survival (not reached vs 16.3 months [range, 2.6-45.1 months]; P = .03) in the RT plus icotinib group.

Conclusions and relevance: In this randomized clinical trial, icotinib plus RT was well tolerated and improved OS in older patients with ESCC relative to RT alone. Patients with EGFR overexpression benefitted more from icotinib with RT.

Trial registration: ClinicalTrials.gov Identifier: NCT02375581.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. CONSORT Diagram of Participant Flow…
Figure 1.. CONSORT Diagram of Participant Flow Through the Trial
Figure 2.. Kaplan-Meier Analyses of Survival in…
Figure 2.. Kaplan-Meier Analyses of Survival in the Intention-to-Treat Population
HR indicates hazard ratio; OS, overall survival; PFS, progression-free survival; and RT, radiotherapy.
Figure 3.. Subgroup Analysis of Icotinib Benefit…
Figure 3.. Subgroup Analysis of Icotinib Benefit for Overall Survival
HR indicates hazard ratio; RT, radiotherapy.

References

    1. Herskovic A, Martz K, al-Sarraf M, et al. . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.. N Engl J Med. 1992;326(24):1593-1598. doi:10.1056/NEJM199206113262403
    1. Minsky BD, Pajak TF, Ginsberg RJ, et al. . INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167-1174. doi:10.1200/JCO.2002.20.5.1167
    1. Tougeron D, Di Fiore F, Thureau S, et al. . Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008;99(10):1586-1592. doi:10.1038/sj.bjc.6604749
    1. Takeuchi S, Ohtsu A, Doi T, et al. . A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol. 2007;30(6):607-611. doi:10.1097/COC.0b013e3180ca7c84
    1. Tao S, Zhang X, Min F, Wu S. Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer. Onco Targets Ther. 2015,8:3087-3094. doi:10.2147/OTT.S92537
    1. Zhang P, Xi M, Zhao L, et al. . Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma? PLoS One. 2014;9(8):e105270. doi:10.1371/journal.pone.0105270
    1. Cui Z, Tian Y, He B, et al. . Associated factors of radiation pneumonitis induced by precise radiotherapy in 186 elderly patients with esophageal cancer. Int J Clin Exp Med. 2015;8(9):16646-16651.
    1. Wakui R, Yamashita H, Okuma K, et al. . Esophageal cancer: definitive chemoradiotherapy for elderly patients. Dis Esophagus. 2010;23(7):572-579. doi:10.1111/j.1442-2050.2010.01062.x
    1. Ajani JA, D’Amico TA, Almhanna K, et al. ; National Comprehensive Cancer Network . Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13(2):194-227. doi:10.6004/jnccn.2015.0028
    1. Pande AU, Iyer RV, Rani A, et al. . Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology. 2007;73(5-6):281-289. doi:10.1159/000132393
    1. Ruhstaller T, Thuss-Patience P, Hayoz S, et al. ; Swiss Group for Clinical Cancer Research (SAKK); German Esophageal Cancer Study Group; Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT); Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Chirurgie (FRENCH) . Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol. 2018;29(6):1386-1393. doi:10.1093/annonc/mdy105
    1. Crosby T, Hurt CN, Falk S, et al. . Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14(7):627-637. doi:10.1016/S1470-2045(13)70136-0
    1. Suntharalingam M, Winter K, Ilson D, et al. . Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the nrg oncology rtog 0436 phase 3 randomized clinical trial. JAMA Oncol. 2017;3(11):1520-1528. doi:10.1001/jamaoncol.2017.1598
    1. Chinnaiyan P, Huang S, Vallabhaneni G, et al. . Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8):3328-3335. doi:10.1158/0008-5472.CAN-04-3547
    1. Tortora G, Gelardi T, Ciardiello F, Bianco R. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int J Biol Markers. 2007;22(1 suppl 4):S47-S52. doi:10.1177/17246008070221s406
    1. Tan F, Shen X, Wang D, et al. . Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012;76(2):177-182. doi:10.1016/j.lungcan.2011.10.023
    1. Wang X, Niu H, Fan Q, et al. . Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma. Oncotarget. 2016;7(17):24744-24751. doi:10.18632/oncotarget.8271
    1. Zhai Y, Hui Z, Wang J, et al. . Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study. Dis Esophagus. 2013;26(5):503-509. doi:10.1111/j.1442-2050.2012.01380.x
    1. Liang J, E M, Wu G, et al. . Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a phase ii clinical trial. Onco Targets Ther. 2013;6:1589-1596. doi:10.2147/OTT.S50945
    1. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-115. doi:10.2307/2529712
    1. Atkinson M. Diseases of the alimentary system; dysphagia. Br Med J. 1977;1(6053):91-93. doi:10.1136/bmj.1.6053.91
    1. Xiao-Lu YU, Wang HM, Wang WM. Efficacy of icotinib as first-line therapy for 134 patients with advanced lung adenocarcinoma of positive EGFR mutation. J Chinese Oncol. 2017;23(9):772-775. doi:10.11735/j.issn.1671-170X.2017.09.B006
    1. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988;44(1):229-241. doi:10.2307/2531910
    1. Lakatos E. Designing complex group sequential survival trials. Stat Med. 2002;21(14):1969-1989. doi:10.1002/sim.1193
    1. D'Journo XB, Thomas PA. Current management of esophageal cancer. J Thorac Dis. 2014;6(suppl 2):S253-S264. doi:10.3978/j.issn.2072-1439.2014.04.16
    1. Xu Y, Zheng Y, Sun X, et al. . Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: preliminary results of a phase II study. Oncotarget. 2015;6(35):38429-38439. doi:10.18632/oncotarget.5193
    1. Iyer R, Chhatrala R, Shefter T, et al. . Erlotinib and radiation therapy for elderly patients with esophageal cancer–clinical and correlative results from a prospective multicenter phase 2 trial. Oncology. 2013;85(1):53-58. doi:10.1159/000351617
    1. Cooper JS, Guo MD, Herskovic A, et al. ; Radiation Therapy Oncology Group . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281(17):1623-1627. doi:10.1001/jama.281.17.1623
    1. Hulshof MCCM, Geijsen D, Rozema T, et al. . A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol, 2020,38(suppl 4):281. doi:10.1200/JCO.2020.38.4_suppl.281
    1. Zhang XB, Xie CY, Li WF, Zhang P, Wu SX. [Phase II study of radiotherapy plus erlotinib for elder patients with esophageal carcinoma]. Zhonghua Yi Xue Za Zhi. 2012;92(23):1615-1617.
    1. Niho S, Ohe Y, Ishikura S, et al. . Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Ann Oncol. 2012;23(9):2253-2258. doi:10.1093/annonc/mds012
    1. Komaki R, Allen PK, Wei X, et al. . Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage iii non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;92(2):317-324. doi:10.1016/j.ijrobp.2015.02.005
    1. Ready N, Jänne PA, Bogart J, et al. ; Cancer, Leukemia Group B, Chicago, IL . Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010;5(9):1382-1390. doi:10.1097/JTO.0b013e3181eba657
    1. Petty RD, Dahle-Smith A, Stevenson DAJ, et al. . Gefitinib and egfr gene copy number aberrations in esophageal cancer. J Clin Oncol. 2017;35(20):2279-2287. doi:10.1200/JCO.2016.70.3934
    1. Mehta VK. Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. Front Oncol. 2012;2:31. doi:10.3389/fonc.2012.00031

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa